Theralase Lead Anti-Cancer Drug Effective in the Destruction of Throat Cancer

Stock Information for Theralase Technologies Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Theralase Technologies Inc.

Theralase(R) Closes $CAN 750,000 Non-Brokered Private Placement
Theralase(R) Granted Canadian Cancer Vaccine Patent
Theralase(R) Release's 4Q2023 Interim Financial Statements
Theralase(R) to Host Advisory Board Meetings at Canadian Urological Association Bladder Cancer Forum and the American Urological Association
Theralase(R) Donates Cool Laser Therapy Technology to Aid in Research and Development of a Treatment for Parkinson's Disease
Dr. Michael Jewett Joins Theralase(R) to Help Complete Enrollment in the Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
Theralase(R) Closes $CAN 1.2 Million Non-Brokered Private Placement
Theralase(R) Provides Update on Phase II Bladder Cancer Clinical Study

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.